Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02171949
Other study ID # PCL 03/13
Secondary ID
Status Recruiting
Phase Phase 2
First received June 16, 2014
Last updated November 27, 2017
Start date April 2015
Est. completion date June 2019

Study information

Verified date November 2017
Source Hospital Sao Rafael
Contact André C Lyra, PhD
Phone 557132816455
Email aclyra@live.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of multiple infusions of mononuclear bone marrow cells in patients with chronic liver diseases.


Description:

This is a safety/efficacy phase II, open, randomized, controlled clinical trial, with two arms. The study population will consist of 30 patients with chronic decompensated liver disease (Child-Pugh B or C). The candidates included in the study will be asked to voluntarily participate and sign the written consent.

The patients will be allocated randomly into 2 groups: in group A, the patients will undergo the intervention; and in group B, the patients will be the controls. Patients of both groups will receive clinical follow-up. They will be maintained on drug therapy commonly used in patients with cirrhosis, which may include: spironolactone, furosemide, lactulose, metronidazole, neomycin, analogs of nucleoside / nucleotide in patients with hepatitis B, and vitamin complexes.

All patients included in Group A will undergo cell therapy according to the technique described as follows: on day 1 (D-1), patients will be hospitalized to undergo the bone marrow puncture through the iliac crest. 150 to 200 ml of bone marrow aspirate will be collected. The procedure will be done under local anesthesia and sedation. The fraction of mononuclear cells will be isolated from the aspirated marrow by the SEPAX (System of cell processing) - Biosafe, Switzerland.

The enriched fraction of collected mononuclear cells will be resuspended in saline. The obtained cell populations will be analyzed by flow cytometry for its characterization, and then diluted in 20 ml saline. The cells will be injected 3 times throughout the study, on days 1 (D-1), 30 (D-30) and 60 (D-60).

Patients will undergo a series of clinical and laboratory evaluations and will also be submitted to the following procedures:

- Cell blood count

- Biochemical analysis (measurement of electrolytes - sodium and potassium)

- Renal function tests (urea and creatinine)

- Liver profile tests (total proteins and fractions, bilirubin, prothrombin time, transaminases, alkaline phosphatase, gamma-GT)

- Metabolic profile (glucose, total cholesterol and fractions, triglycerides)

- Thyroid profile tests

- Serology required for blood transfusion and bone marrow transplant in Brazil

- Alpha-fetoprotein

- Beta-HCG (human chorionic gonadotropin), for women

- Handgrip dynamometer

- Treadmill test

- Six-minute walk test

- Abdomen doppler ultrasound

- Magnetic resonance imaging of the upper abdomen with elastography

- Measurement of serum factors

- Shear wave elastography

Also, the patients will respond to questions from the SF (Short Form) -36 questionnaire (for assessment of quality of life).

Clinical follow-up will be kept for patients who suspend their participation in the study for any adverse event and / or laboratory abnormality, or for the patient's own desire, following insurance protocols. In addition to the clinical and surgical follow-up, specific medical care will be offered to patients who experience adverse events, until stabilization of the patient, even if the target date for completion of the study has been exceeded.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date June 2019
Est. primary completion date December 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Diagnosis of liver cirrhosis of different etiologies, confirmed by clinical examination, laboratory tests, imaging studies and / or biopsy that shows process of evolution to cirrhosis or established cirrhosis (equivalent to Metavir score F3/F4);

- Non-participation on the waiting list for liver transplantation or, in case of participation, allocation after the fifth position in the list, for subjects with blood group A or O, and after the third position for subjects with other blood groups;

- Absence of clinical, laboratory and radiological evidence of hepatocellular carcinoma;

- Absence of pregnancy potential or negative pregnancy test for female patients, or impossibility to use a contraception method during the study;

- Permission for doing the puncture of iliac crest after evaluation of pre-anesthetic visit.

Exclusion Criteria:

- Impossibility to obtain vascular access for percutaneous procedure;

- Sepsis;

- Hepatic encephalopathy detected at the screening tests;

- Budd-Chiari syndrome;

- Severe coagulopathy with INR > 2,4 or platelet count < 30.000;

- Presence of malignancies (excluding non-melanoma skin cancer);

- Decompensated heart failure;

- Primary hematologic diseases;

- Renal failure with creatinin > 2,5mg/dl;

- Coinfection with HIV;

- Pregnancy;

- Dependence of organic medium such as circulatory or ventilatory;

- Any other comorbidity with an impact on the survival in 2 years;

- Participation in other clinical trial.

Study Design


Intervention

Biological:
Infusion of bone marrow mononuclear cells.
Patients on this group will receive therapy with mononuclear cells. The cells will be diluted on saline and then injected on the hepatic artery through femoral artery puncture.

Locations

Country Name City State
Brazil Hospital São Rafael Salvador Bahia

Sponsors (3)

Lead Sponsor Collaborator
Hospital Sao Rafael Ministry of Health, Brazil, Ministry of Science and Technology, Brazil

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of Child-Pugh score Functional class improvement of 2 points on Child-Pugh score. 12 months
Primary Evaluation of MELD score Functional class improvement of 2 points on MELD score. 12 months
Secondary Degree of muscle strength Improvement in the degree of muscle strength assessed using handgrip dynamometer. 12 months
Secondary Hepatic fibrosis Decrease of hepatic fibrosis detected by elastography shear waves. 12 months
Secondary Quality of life Improvement on the SF-36 questionnaire score, which evaluates quality of life. 12 months
Secondary Evaluation of functional capacity Improvement in the functional capacity, assessed by six-minute walk test. 12 months
Secondary Evaluation of serum bilirubin levels Improvement in the serum bilirubin levels. 12 months
Secondary Evaluation of serum albumin levels Improvement in the serum albumin levels. 12 months
Secondary Evaluation of prothrombin time Improvement in prothrombin time. 12 months
Secondary Evaluation of serum levels of cytokines Decrease in the serum levels of cytokines. 12 months
Secondary Evaluation of fibrosis markers levels Decrease in the serum levels of fibrosis markers. 12 months
See also
  Status Clinical Trial Phase
Completed NCT01349348 - Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites Phase 3
Active, not recruiting NCT04682847 - Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
Recruiting NCT05904470 - A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV Phase 2
Completed NCT02138253 - A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV Phase 2
Recruiting NCT02652351 - Human Umbilical Cord-Mesenchymal Stem Cells for Hepatic Cirrhosis Phase 1
Completed NCT00794482 - Multi-national Cirrhosis Study to Characterise the Association Between the Pharmacokinetics of NRL972 and Disease Severity. Phase 3
Completed NCT00856713 - Clearance of NRL972 in Patients With Cirrhosis and in Healthy Volunteers Phase 1
Completed NCT02163512 - Effect of Beta-adrenergic Blockers on Cardiac Function, Systemic and Splanchnic Haemodynamic and Kidney Function in Cirrhotic Patiets With Refractory Ascites
Completed NCT00857480 - Evaluation of the PK of NRL972 Following Pre- and co-Administration of Ursodeoxycholic Acid and Cloxacillin Phase 1
Completed NCT00006164 - Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment Phase 3
Completed NCT03486912 - A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis Phase 2
Completed NCT00698464 - Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function Phase 1
Completed NCT02778425 - The Treatment of Hepatocirrhosis and Portal Hypertension N/A
Completed NCT03445208 - A Study of Experimental Medication BMS-986036 Given to Healthy Participants Phase 1
Completed NCT03420768 - A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C Phase 2
Completed NCT03804593 - HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC)
Completed NCT03712280 - MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy) Phase 2
Completed NCT02230683 - A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension Phase 2
Completed NCT02230670 - A Study of IDN-6556 in Subjects With Liver Cirrhosis Phase 2
Completed NCT01135628 - Hyperproteic Diet Plus Lactobacillus Reuteri and Nitazoxanide in Minimal Hepatic Encephalopathy N/A